The rationale behind this combination strategy relates to the involvement of CXCR4 and its ligand CXCL12 in supporting tumor cell growth and angiogenesis, as well as immunosuppression in the tumor microenvironment [110]. The gene discussed is CXCL12; the disease is neoplasm.